FDA streamlines process for Warning Letters

Share this article:
The days of getting an FDA Warning Letter after the subject promotional campaign has concluded may be over, if new internal initiatives to collapse the operational timeframes in the drug center's compliance and enforcement sectors bear fruit.

For years, FDA slowness in catching up with regulatory violations could be “taken to the bank.” When a letter eventually arrived from the agency, the matter complained about had frequently run its natural course and the expense of explaining this to FDA could be written off as a “cost of doing business.”

Since her enforcement initiative was announced, commissioner Margaret Hamburg has been directing resources into pressure points, including the CDER's Office of Compliance and the DDMAC.

“We have streamlined our processes for the drafting and review of untitled and warning letters,” DDMAC director Tom Abrams said in June. “We have also dedicated additional resources to enforcement. As a result we have a significant increase in these letters and they have become more timely.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.